Sapphire Technologies

Sapphire Biotech is a biotechnology company focused on the development of novel cancer diagnostics and therapeutics, as well as plant-based biotechnologies. As a subsidiary of 22nd Century Group, the company leverages a proprietary platform to identify and target proteins involved in cancer cell proliferation and metastasis, such as HSP90 and PDI. Their research efforts are directed toward creating high-affinity small molecules that can inhibit these targets to treat aggressive and drug-resistant cancers. Additionally, Sapphire Biotech specializes in the development of biotechnological methods for the production of pharmaceutical-grade cannabinoids. The company's dual focus on oncology and cannabinoid science aims to address significant unmet needs in both therapeutic and diagnostic markets.